<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3017">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810637</url>
  </required_header>
  <id_info>
    <org_study_id>GXI7KGBio-001</org_study_id>
    <nct_id>NCT04810637</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19</brief_title>
  <official_title>A Phase 2, Randomized, Double Blinded, Placebo Controlled, Parallel Group, Single Administration Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Kalbe Genexine Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PT Kalbe Genexine Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 prospective, randomized, placebo-controlled, double-blinded, parallel&#xD;
      group, single administration, multi-center study to assess the safety and efficacy of&#xD;
      efineptakin alfa single treatment compared to placebo in elderly participants (adults&#xD;
      ≥50years) with asymptomatic or mild COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 2 parts:&#xD;
&#xD;
      Part I - to identify the Recommended Phase 2 Dose (RP2D) compared to placebo in elderly&#xD;
      participants (adults ≥50 years) with asymptomatic or mild COVID-19. These patients will be&#xD;
      treated with 120 and 240 µg/kg efineptakin alfa, given on Day 1 (Baseline), respectively. The&#xD;
      study will evaluate the safety, tolerability, and pharmacodynamics variable (ALC) of&#xD;
      efineptakin alfa against COVID-19.&#xD;
&#xD;
      Part II - to assess the safety and efficacy of efineptakin alfa single treatment compared to&#xD;
      placebo in elderly participants with asymptomatic or mild COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded phase 2 controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dose finding</measure>
    <time_frame>9 weeks</time_frame>
    <description>MTD and RP2D based on safety profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute lymphocyte count (ALC)</measure>
    <time_frame>9 weeks</time_frame>
    <description>The change of absolute lymphocyte count from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related Adverse Events</measure>
    <time_frame>10 weeks</time_frame>
    <description>The proportion of participants with treatment emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of COVID-19 infection</measure>
    <time_frame>9 weeks</time_frame>
    <description>Decrease of viral shedding identified with nasopharyngeal swab specimen by RT-PCR test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of GX-I7 in patients with COVID-19</measure>
    <time_frame>9 weeks</time_frame>
    <description>The proportion of participants who have progressed to moderate or severe or critical illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in clinical parameters</measure>
    <time_frame>9 weeks</time_frame>
    <description>Time to clinical improvement: clinical improvement is defined as a ≥ 2-point improvement in clinical status (8-point ordinal scale) from Day 1 (baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess in improvement in clinical parameters</measure>
    <time_frame>9 weeks</time_frame>
    <description>Time to ≥ 1-point improvement (days) from Day 1 (baseline) in terms of clinical status</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune repertoire in the study population</measure>
    <time_frame>9 weeks</time_frame>
    <description>Changes of the rate of different immune cell types (i.e, effector/ memory T cell) and regulatory T cell (i.e, Tregs) in the blood after a single efineptakin alfa treatment, if possible</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>GX-I7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised on experimental arm will receive GX-I7 drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GX-I7 vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomised on comparator arm will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-I7</intervention_name>
    <description>Recombinant human interleukin-7 hybrid Fc</description>
    <arm_group_label>GX-I7</arm_group_label>
    <arm_group_label>GX-I7 vehicle</arm_group_label>
    <other_name>Efineptakin alfa NT-I7</other_name>
    <other_name>rhIL-7-hyFc</other_name>
    <other_name>NT-I7</other_name>
    <other_name>TJ107</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 50 years and above at the time of consent&#xD;
&#xD;
          2. Subjects who have been confirmed to be COVID-19 corresponding to asymptomatic case or&#xD;
             mild cases of severity categorization classified by FDA through authorized molecular&#xD;
             saliva-based test or polymerase chain reaction (PCR) test and who can be available to&#xD;
             be administered within 7 days from the onset of any symptoms.&#xD;
&#xD;
          3. Patients who provide a voluntarily consent to participate in the study and sign the&#xD;
             consent form in his/her own handwriting.&#xD;
&#xD;
          4. Female patients of childbearing potential (including female received a tubal ligation)&#xD;
             should be prove negative pregnancy through pregnancy test before 24 hours of the IP&#xD;
             administration, and must be willing to maintain abstinence (restraint sexual&#xD;
             relationships) or use an adequate method of contraception at least 90 days after the&#xD;
             IP administration.&#xD;
&#xD;
          5. Male patients must be willing to maintain abstinence (restraint sexual relationships)&#xD;
             or use of adequate contraception method, and not to donate sperm. Men with&#xD;
             childbearing or pregnant female spouses should maintain abstinence or use condoms at&#xD;
             least 90 days after the IP administration to avoid exposure to embryos&#xD;
&#xD;
          6. Patients who agree for the hospitalisation (however, the hospitalisation will be&#xD;
             performed only if needed)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are unable to follow clinical and follow-up procedures&#xD;
&#xD;
          2. Patients with symptoms of moderate or higher in the severity classification presented&#xD;
             by FDA have evidence of lower respiratory tract infection in their imaging findings or&#xD;
             need supplemental oxygen therapy or mechanical respiration (ie, non-invasive&#xD;
             ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation,&#xD;
             etc)&#xD;
&#xD;
          3. Patients who have clinically significant cardiovascular diseases such as myocardial&#xD;
             infarction, unstable arrhythmia and/or unstable angina within 3 months&#xD;
&#xD;
          4. Patients who have uncontrolled type II diabetes mellitus (despite the proper use of&#xD;
             the drug, if fasting blood sugar level is not controlled to be more than 200 mg/dL)&#xD;
&#xD;
          5. If the principal investigator determines that patients are ineligible or difficult to&#xD;
             follow the protocol due to evidence of severe or unregulated systemic diseases,&#xD;
             uncontrolled hypertension (despite the proper use of the drug, if the blood pressure&#xD;
             is not controlled to be lower than 150/90 mmHg), and active bleeding tendency&#xD;
&#xD;
          6. Patients who are known to be HIV positive&#xD;
&#xD;
          7. Patients who are known to be B-type, or C-type hepatitis-positive carrier&#xD;
&#xD;
          8. Patients who are pregnant or breastfeeding&#xD;
&#xD;
          9. Patients suspected of or identified with a malignant tumor or have a history of tumors&#xD;
             within the past 5 years&#xD;
&#xD;
         10. Patients with the infectious diseases such as bacteremia or severe pneumonia requiring&#xD;
             active treatment within four weeks prior to the IP administration&#xD;
&#xD;
         11. Patients with immunodeficiency or autoimmune diseases that can be exacerbated through&#xD;
             immunotherapy at present&#xD;
&#xD;
         12. Patients who have previously received an allogeneic marrow transplantation or solid&#xD;
             organ transplantation&#xD;
&#xD;
         13. Patients who are currently taking other drugs such as immunosuppressants that may&#xD;
             affect the results of the study&#xD;
&#xD;
         14. Patients who have severe allergy for humanized antibodies or fusion proteins,&#xD;
             anaphylaxis, or other hypersensitivity&#xD;
&#xD;
         15. Patients who have received other IP administration while participating in another&#xD;
             clinical trial within 30 days prior to the IP administration for this study (However,&#xD;
             biological preparation shall be applied to 60 days and even longer period can be&#xD;
             applied considering the half-life) -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paritosh Keertikar, PhD</last_name>
    <phone>+65 9730 6164</phone>
    <email>paritosh.keertikar@innogene.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Artati A, MBBS</last_name>
    <phone>+62 812-9262-727</phone>
    <email>artati@kalbe.co.id</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mitra Keluarga Kelapa Gading</name>
      <address>
        <city>Jakarta Pusat</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Frans Liwang, SpPD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mitra Keluarga Kemayoran</name>
      <address>
        <city>Jakarta Pusat</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Candra Wibowo, SpPD-KGH FINASIM</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

